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DNA fingerprinting has demonstrated predominance of the Beijing genotype
among Mycobacterium tuberculosis strains isolated in Southeast Asia. We
prospectively examined the occurrence of Beijing genotype strains in tuber-
culosis patients in Indonesia. Early in treatment, patients infected with
Beijing genotype strains more often had fever unrelated to disease severity,
toxicity, or drug resistance, indicating that Beijing genotype strains may
have specific pathogenic properties. 
In 1995, DNA fingerprinting showed that >80% of a col-
lection of  Mycobacterium tuberculosis isolates from China
belonged to a genetically closely related group of bacteria,
the Beijing genotype family (1). Strains of this genotype fam-
ily also dominated in neighboring countries in Southeast
Asia, whereas prevalence was lower on other continents (1).
In a recent study, 50% of 563 isolates from Vietnam belonged
to the Beijing genotype; moreover, the occurrence of these
strains correlated strongly with young age and hence with
active transmission of tuberculosis (TB) (2). Strains of the
Beijing family were thought to have expanded recently from
an evolutionary lineage with an unknown selective advan-
tage over other M. tuberculosis genotypes (1). Strain W, a
highly drug-resistant strain that caused large nosocomial
outbreaks in New York City in the early 1990s (3,4), is an
evolutionary branch of the Beijing genotype family (5).
Worldwide, Indonesia has the third highest number of
TB patients, with an estimated 591,000 cases in 1998 (6). No
data have been published from Indonesia on the distribution
of M. tuberculosis genotypes. 
The Study
We prospectively collected demographic and clinical
data and performed DNA fingerprinting of M. tuberculosis
isolates from a  cohort of patients in Jakarta. We assessed
prevalence of the Beijing genotype strains and compared
drug resistance and clinical course of patients infected with
Beijing and other genotype strains of M. tuberculosis. 
From December 1998 through March 1999, 121 consecu-
tive patients were enrolled at Perkumpulan Pembertasan
Tuberkulosa Indonesia, an outpatient TB clinic in a densely
populated area in Jakarta. Informed consent was obtained
from all patients. Demographic data, symptoms and signs,
risk factors for TB, and details about previous antituberculo-
sis therapy were recorded. From three large-volume sputum
samples, microscopy for acid-fast bacilli (AFB) and culture
for  M. tuberculosis  were performed. Chest X-rays taken
before start of treatment were evaluated by two experienced
pulmonologists. HIV status was determined. When TB was
bacteriologically confirmed, a standard four-drug regimen
(isoniazid [INH], rifampicin, pyrazinamide, and ethambutol)
was prescribed (7). During follow-up examinations, symp-
toms, body temperature, and weight were recorded. 
After standard processing of sputum samples, culture
was performed in 3% Ogawa’s medium. Twice a week, slants
were examined for colonies. At the National Institute of Pub-
lic Health and the Environment (RIVM), Bilthoven, the
Netherlands, susceptibility testing of patient isolates was
done by using serial dilutions of five antituberculosis drugs
on Middlebrook’s medium (8). For pyrazinamide, the same
method was used after pH of the medium was adjusted to
5.70–5.75. MICs used to define drug resistance were INH 0.2
mg/L, rifampicin 1 mg/L, ethambutol 5 mg/L, streptomycin 5
mg/L, and pyrazinamide 50 mg/L.
Genotyping of mycobacterial isolates was done by
restriction fragment length polymorphism (RFLP) typing.
Extraction of DNA from M. tuberculosis strains and South-
ern blotting with labeled IS6110 DNA as a probe were done
by a standard DNA fingerprinting method (9). Spacer oligo-
nucleotide typing (spoligotyping) of  M. tuberculosis DNA
from patient isolates was done as described (10). This
method reliably identifies Beijing genotype strains on the
basis of specific reaction with only 9 (35 to 43) of the 43 spac-
ers used in spoligotyping (1,2). All the identified Beijing gen-
otype strains also had highly similar but in most cases not
identical IS6110 RFLP patterns, with a high number of
bands. From culture-negative patients, M. tuberculosis DNA
for spoligotyping was directly isolated from sputum smears
(11). Computer-assisted analysis of IS6110 fingerprints and
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spoligotyping patterns was done with Bionumerics 4.0
(Applied Maths, Kortrijk, Belgium). 
Descriptive result sare reported as median (range) for
continuous variables and as percentages for categorical data.
The Mann-Whitney U test was used for comparison of con-
tinuous variables and the Pearson chi-square test for propor-
tions. The level of significance was p<0.05. 
In 121 consecutive patients with a clinical diagnosis of
TB, direct examination of at least one sputum smear was
positive for AFB in 89 (73%), and M. tuberculosis was cul-
tured from 83 (73%) of 113 cultures performed. IS6110
restriction fragment patterns were analyzed in combination
with the respective spoligopatterns of these samples (Fig-
ure). Most (90%) strains had a fingerprint pattern that dif-
fered from the RFLP patterns of other strains in this study. 
Four miniclusters of two identical RFLP patterns were
found. Besides visiting the same clinic, no epidemiologic con-
nection could be made between patients infected with these
strains. Laboratory contamination seems unlikely, as patient
specimens were collected on separate days. DNA of two iso-
lates did not show hybridization with the IS6110 probe, but
yielded positive reactions in spoligotyping. Such M. tubercu-
losis strains without IS6110 DNA have been described (12).
Twenty-seven strains had a high number of IS6110-contain-
ing restriction fragments and a high degree of similarity
(>66%) among patterns. This homogeneous group of isolates
represented the Beijing family of genotypes, as confirmed by
spoligotyping (Figure). Direct spoligotyping on sputum
smears of culture-negative patients added another four
patients with Beijing strain infections. Of 92 M. tuberculosis
strains analyzed (83 cultured isolates by IS6110 RFLP and
spoligotyping and 9 stained sputum smears by spoligotyping
only), 31 strains (34%) were Beijing genotypes.
Cultures became positive for  M. tuberculosis after 4.7
weeks for Beijing strains, compared with 5.2 weeks for other
strains. As in a recent study in Vietnam, drug susceptibility
testing showed a trend toward higher prevalence of resis-
tance to INH (37% vs. 20%; p=0.09) and streptomycin (15%
vs. 5%; p=0.16) in Beijing strains compared with other
strains; however, these differences did not attain statistical
significance. (Table). The two groups did not differ signifi-
cantly in prevalence of multidrug resistance (7% vs. 4%). For
both Beijing and other strains, drug resistance was found
equally among age groups (data not shown).
The characteristics of patients infected with Beijing gen-
otypes (n=31) were compared with those of patients infected
with other strains (n=61) (Table). The age distribution in the
two groups was similar, although no patients <16 years of
age were evaluated. No relation was found between genotype
and BCG vaccination status (Table). Of the patients infected
with Beijing strains, 7 (23%) had received one or more anti-
tuberculosis drugs before, compared with 18 (29%) of
patients infected with other strains. Only two patients (one
in each group) had been prescribed a standard four-drug reg-
imen for 6 months. On entering the study, patients did not
differ significantly in the presence of fever, dyspnea, or
hemoptysis, or in duration of symptoms (data not shown).
The nutritional status in both groups of patients was similar,
as judged by body mass index (17 vs. 16.9 kg/m2). The num-
ber of smear-positive patients and the AFB density in spu-
tum smears were similar in both groups (data not shown).
Patients did not differ significantly by X-ray evaluation; the
number of lung fields involved was similar, and an equal per-
centage in both groups had pulmonary cavities (Table). Only
one patient, whose initial diagnosis was cavitary TB, was
HIV positive; this patient was infected with a Beijing strain.
Patients were evaluated weekly. Most patients had an
early, beneficial response to treatment. In both groups, 20%
continued to lose weight during the first 2 months of the
study. This loss was small (approximately 1 kg) and may
have been due to observance of the Ramadan fast. Body
weight increased a median of 2 kg (range 0 to 8 kg) in the
remaining patients in both groups. No relation was found
between drug resistance and changes in body weight. At 6
months, patients in both groups had gained weight equally
(median 5 kg). No patient had active disease at this point,
but treatment was extended in patients infected with strains
resistant to multiple drugs. 
Thirty-two percent of patients developed fever (>38°C,
maximum 39.3°C) during the first weeks of treatment. No
patient reported shaking chills during this period. This
transient febrile response, which lasted 2 to 3 weeks, was
found in 15 (48%) of 31 patients infected with Beijing
strains compared with 13 (21%) of 61 patients with other
strains (relative risk 2.3; 95% confidence interval 1.1–4.7).
Drug resistance could not account for this finding: 46% of
Figure. Dendrogram showing similarity of the 83 IS6110 restriction
fragment length polymorphism patterns of  Mycobacterium tubercu-
losis isolates from Jakarta, in combination with the respective spoli-
gotype patterns. The branch in the dendrogram representing Beijing
genotype isolates is indicated with an asterisk (*).Dispatches
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patients infected with a fully susceptible Beijing strain com-
pared with 19% of patients infected with susceptible non-
Beijing strains had a febrile response (p=0.06). Neither did
severity of disease account for the difference, as the febrile
response was not associated with nutritional status or pres-
ence of pulmonary cavities (data not shown). Drug toxicity,
which may also induce fever, was not established.
Conclusions
Worldwide, DNA fingerprinting has revealed extensive
heterogeneity of  M. tuberculosis genotypes (13). However, a
distinct and predominant M. tuberculosis genotype, termed
Beijing, has been found in the People’s Republic of China and
neighboring countries (1,14). Our study demonstrates that
Beijing strains are also present in the Indonesian archipelago.
The prevalence of Beijing strains in China (85%), Mon-
golia (50%), South Korea (43%), Thailand (37%), Vietnam
(50%), and Indonesia (34%) suggests that this clone spreads
in Southeast Asia, where TB is endemic. Beijing genotype
strains also account for a substantial proportion of multi-
drug-resistant TB cases in Azerbaijan and Estonia (15,16)
and Cuba (17). Strain W, which also belongs to the Beijing
genotype family (5), caused major outbreaks of multidrug-
resistant TB during the past decade in the United States
(3,4) and South Africa (18). In summary, all reports on the
occurrence of Beijing genotypes show a clear correlation with
drug resistance. In our study, 37% of the Beijing strains were
resistant to INH. However, multidrug resistance was lim-
ited, making drug resistance unlikely as a single explanation
for the predominance of Beijing strains in this population. 
Different transmission rates may account for an
unequal distribution of genotypes. In a TB outbreak in the
United States, a particular M. tuberculosis genotype caused
extensive transmission, as evaluated by skin test conversion
(19). In Indonesia, outbreak investigations like these seem
impossible in light of the high prevalence of TB and standard
BCG vaccination, which hampers interpretation of tubercu-
lin skin tests. However, indirect evidence supporting
increased transmission of Beijing strains comes from a
recent study in Vietnam, which demonstrated that Beijing
strains were more prevalent among young patients (2). We
could not confirm this in the Indonesian patients, but we did
not investigate patients <16 years of age. In agreement with
the study in Vietnam, we found no correlation between vacci-
nation status and genotypes. 
Disease severity in patients infected with Beijing or
other genotypes seemed similar. However, our prospective
evaluation revealed a different response to treatment. Forty-
eight percent of the patients infected with Beijing strains
and 21% of the patients infected with other strains had a
transient febrile response shortly after start of treatment.
Disease severity, drug toxicity, and drug resistance could not
account for this difference. The increased risk of febrile
response in patients infected with Beijing strains is unusual
and suggests that these strains induce a different host
response. In support of this hypothesis, Beijing genotype
strains were recently found to elicit an altered cytokine
response in two animal models (D. van Soolingen, unpub.
data). This differential response may be related to the rapid
spread of Beijing genotype strains. There may be an interest-
ing parallel with the outbreak in the United States (19),
since the causative strain in that outbreak, designated
CDC1551, induced a more rapid and robust in-vitro produc-
tion of pyrogenic cytokines such as interleukin-6 and tumor
necrosis factor-a (20). Whether Beijing strains also elicit a
different cytokine response in TB patients is a subject for
future study. 
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Table. Drug resistance and patient characteristics by







Male 19 (61) 35 (57)
Age in years, median 
(range) 
31 (19-68) 29 (17-70)
BCG scar 8 (26) 14 (23)
Chest X-ray
    cavities





Febrile response to 
treatmentb
15 (48) 13 (21)
Patient strain resistant toc n = 27 (%) n = 56 (%)
Isoniazid 10 (37) 11 (20)
Rifampicin 2 (7) 2 (4)
Pyrazinamide 0 3 (5)
Ethambutol 1 (4) 3 (5)
Streptomycin 4 (15) 3 (5)
Any prescribed drug  11 (39) 14 (25)
aSix chest X-rays in the non-Beijing group were evaluated by only one
pulmonologist.
bSignificant difference between groups (Mann-Whitney U-test; p=0.02). 
c Eighty-three isolates were available for drug susceptibility testing.Dispatches
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